Vortioxetine as adjunctive treatment of negative symptoms in patients with schizophrenia: a double blind and placebo controlled trial

Trial Profile

Vortioxetine as adjunctive treatment of negative symptoms in patients with schizophrenia: a double blind and placebo controlled trial

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 22 Dec 2017

At a glance

  • Drugs Vortioxetine (Primary) ; Risperidone
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Dec 2017 According to IRCT201710241556N100, Expected recruitment end date will be 8 Nov 2019 (planned).
    • 20 Dec 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top